What is Liraglutide? Learn About Its Uses, Dosage & Side Effects
Discover what liraglutide is, how it works for diabetes and weight loss, its side effects, and how it compares to newer drugs like semaglutide.
Learn about liraglutide side effects, from common gastrointestinal issues to rare serious risks. Discover tips to manage symptoms and ensure safe use.
Most side effects are mild and improve over time. Liraglutide side effects can vary from person to person, but there are several common side effects that users should be aware of, including symptoms of a severe allergic reaction.
The most frequently reported side effects of liraglutide are gastrointestinal. These may include nausea, vomiting, diarrhea, and constipation. Some patients also experience abdominal pain or discomfort.
These side effects are often most pronounced when starting treatment or increasing the dose of liraglutide. It's important to note that while these side effects can be uncomfortable, they usually subside as your body adjusts to the medication.
These typically occur during dose escalation and subside within days or weeks.
{{primary-cta}}
Consider making dietary adjustments to manage gastrointestinal side effects. Eating smaller, more frequent meals and avoiding fatty or spicy foods may help reduce nausea and digestive discomfort. Staying well-hydrated and incorporating fiber-rich foods into your diet can also help alleviate constipation associated with liraglutide use.
While rare, these may require medical attention:
Dizziness is another common side effect of liraglutide. Symptoms may be more noticeable during the initial stages of treatment. Risk increases if liraglutide is combined with insulin or sulfonylureas. Symptoms include:
Prevention: Monitor blood sugar levels and adjust other medications under medical supervision.
Liraglutide is administered via injection, and some patients may experience reactions at the injection site. These can include redness, swelling, or itching.
Proper injection techniques and rotating injection sites can help minimize the occurrence of injection-site reactions.
If you notice any severe or persistent injection site reactions, consult your healthcare provider for guidance.
Rotate injection sites (abdomen, thigh, upper arm) to reduce irritation.
If you experience severe or persistent headaches, you must inform your healthcare provider, as these could be signs of more serious complications. Headaches have been reported in 5–10% of users, often resolving within weeks.
Though rare, these side effects require immediate medical intervention:
Symptoms include severe abdominal pain that may radiate to your back, nausea, and vomiting. A PMC study notes pancreatitis incidence is <1% but demands urgent care.
If you experience these symptoms, stop using liraglutide and get medical help. Your healthcare provider will evaluate whether it's safe for you to continue using liraglutide after recovering from pancreatitis.
One of the most serious concerns associated with liraglutide is the potential risk of thyroid cancer. Liraglutide carries a black box warning for thyroid tumors in animal studies. Human risk remains unconfirmed but avoid use if you have a personal/family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Contact your healthcare provider if you experience symptoms such as a lump or swelling in your neck, difficulty swallowing, or shortness of breath.
{{primary-cta}}
Dehydration from severe vomiting or diarrhea may worsen kidney function, particularly in those with pre-existing conditions. When the body loses excessive fluids through these symptoms, blood volume decreases significantly, reducing blood flow to vital organs, including the kidneys.
This reduced perfusion forces the kidneys to work harder with less resources, potentially causing acute kidney injury. Individuals with chronic kidney disease, diabetes, hypertension, or advanced age face substantially higher risks during these episodes.
Patients should seek medical attention promptly if vomiting or diarrhea persists beyond 24 hours, especially if accompanied by decreased urination, dark-colored urine, extreme fatigue, or confusion, as these may indicate severe kidney stress requiring immediate intervention.
Symptoms like persistent or intermittent abdominal pain (particularly in the upper right quadrant), unexplained fever that may come and go, or jaundice (a yellowing of the skin and eyes) may indicate the presence of gallstones or inflammation of the gallbladder.
These severe conditions require immediate medical attention and should not be ignored. Although these adverse effects were reported in ~1.5% of participants who completed the long-term clinical trials, they are relatively uncommon but still significant enough to warrant careful monitoring.
Other associated symptoms might include nausea, vomiting, clay-colored stools, or dark urine, which further suggest potential liver or gallbladder complications.
Data synthesized from Victoza and PMC studies:
*Risk increases with concomitant insulin use.
Contraindications include:
Proper storage and handling of liraglutide are essential for maintaining its effectiveness and safety. Store unused pens in the refrigerator between 36°F to 46°F (2°C to 8°C). Once in use, pens can be stored at room temperature (below 86°F or 30°C) or in the refrigerator for up to 30 days. Never freeze liraglutide, and discard the pen if it has been frozen. Always check the expiration date before use.
{{primary-cta}}
Liraglutide may interact with other medications, potentially affecting their efficacy or increasing the risk of side effects. Inform your healthcare provider about all medicines you take, including prescription drugs, over-the-counter medications, vitamins, and herbal supplements. Patients should pay particular attention to drugs that may increase the risk of hypoglycemia when used in combination with liraglutide.
Liraglutide is a helpful tool for treating metabolic health, and awareness of side effects ensures safe use. Most issues are manageable, and serious complications are rare. Always consult your healthcare provider to weigh the benefits against the risks.
Always consult your healthcare provider about any concerns or questions regarding side effects, especially if you have severe symptoms of a serious allergic reaction. Report any unusual or severe side effects to the FDA. With proper management and communication with your healthcare team, you can optimize your diabetes or weight loss treatment while minimizing potential risks.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
GI symptoms typically resolve within 4–8 weeks as the body adjusts.
Yes—reduced appetite is a common effect, aiding weight management.
Most cases resolve with discontinuation, but severe instances require hospitalization.
Long-term studies show no significant cardiovascular risks, but thyroid/kidney monitoring is advised.
Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obesity Science & Practice. 2017;3(1):3-14. https://doi.org/10.1002/osp4.84
Victoza (liraglutide) Official Website. Possible Side Effects. Novo Nordisk. Updated 2023. https://www.victoza.com/faq/possible-side-effects.html
Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015;373(1):11-22. https://www.nejm.org/doi/full/10.1056/nejmoa1411892
Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021;46:101102. https://www.sciencedirect.com/science/article/pii/S2212877820301502
Faillie JL, Yu OH, Yin H, Hillaire-Buys D, Barkun A, Azoulay L. Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus. JAMA Internal Medicine. 2016;176(10):1474-1481. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2537358
Abd El Aziz M, Cahyadi O, Meier JJ, Schmidt WE, Nauck MA. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes, Obesity and Metabolism. 2020;22(4):699-704. https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.13921
Petersen AB, Knop FK, Christensen M. Liraglutide and Renal Outcomes in Type 2 Diabetes: Results From the LEADER Trial. Diabetes Care. 2022;45(5):1230-1237. https://diabetesjournals.org/care/article/45/5/1230/144859/Liraglutide-and-Renal-Outcomes-in-Type-2-Diabetes
Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018;27(4):740-756. https://www.sciencedirect.com/science/article/pii/S1550413118301967
O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. The Lancet. 2018;392(10148):637-649. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31773-2/fulltext
American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2023. Diabetes Care. 2023;46(Supplement_1):S140-S157. https://diabetesjournals.org/care/article/46/Supplement_1/S140/148032/9-Pharmacologic-Approaches-to-Glycemic-Treatment